AlloVir raises $126.6M in registered direct offering at $4.61/share for Phase 3 trials

Kalaris Therapeutics, Inc.

Sold 27.46M shares at $4.61 each; gross proceeds ~$126.6M.
Funds to complete enrollment and data readouts in three ongoing Phase 3 trials of posoleucel.
New investors include Kite (Gilead), F2 Ventures, ElevateBio, Invus, Redmile, EcoR1 Capital, GMT Capital.
Offering expected to close July 28, 2022; no underwriter. Cash & equivalents $172.7M as of June 30, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.